Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma

Ibrutinib (Imbruvica®), a small-drug inhibitor of Bruton tyrosine kinase (BTK), is currently undergoing clinical testing in patients with multiple myeloma (MM), yet important questions on the role of BTK in myeloma biology and treatment are outstanding. Using flow-sorted side population (SP) cells f...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Res
Main Authors: Yang, Ye, Shi, Jumei, Gu, Zhimin, Salama, Mohamed E, Das, Satyabrata, Wendlandt, Erik, Xu, Hongwei, Huang, Junwei, Tao, Yi, Hao, Mu, Franqui, Reinaldo, Levasseur, Dana, Janz, Siegfried, Tricot, Guido, Zhan, Fenghuang
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4384656/
https://ncbi.nlm.nih.gov/pubmed/25589346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2362
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki